Colitis, which is a common side effect among those undergoing anti-cancer therapy, can be prevented by the consumption of vitamin D supplements, a new study claims. It has been found in older studies that vitamin D may play a role in the immune system in the case of those suffering from inflammatory bowel disease and autoimmune disorders.
Osama Rahma of the Dana-Farber Cancer Institute and Harvard Medical School, in Boston, said in a statement, "Our findings of a link between vitamin D intake and reduced risk for colitis could potentially impact practice if validated in future prospective studies."
A Side Effect of Cancer Treatment
Immune checkpoint inhibitors help the immune system recognize and combat cancer cells, and although these treatments have helped many patients and have prolonged lives, they can cause side effects such as colitis, an inflammatory reaction in the colon.
"Immune checkpoint inhibitor-induced colitis can limit the use of such life-saving drugs leading to discontinuation of treatment. There is a lack of understanding of the risk factors that could be modified to prevent colitis," said Rahma in a paper published in the journal CANCER.
Rahma and his colleagues conducted a study that examined whether taking vitamin D supplements might reduce the risk of colitis in patients receiving immune checkpoint inhibitors to treat their cancer.
Lower Chances of Developing Colitis
The study included information on 213 patients with melanoma who received immune checkpoint inhibitors between 2011 and 2017. Patients who took vitamin D had 65 percent lower odds of developing colitis, after adjustments for confounding factors.
These findings were validated in another group of 169 patients, of whom 49 (29 percent) developed colitis. In this validation group, use of vitamin D was linked with 54 percent lower odds of developing colitis.
"Vitamin D supplementation should be tested further to determine if it could be a safe, easily accessible, and cost-effective approach towards preventing immunotherapy's gastrointestinal toxicity and extending the effectiveness of immune checkpoint inhibitor treatment in cancer patients," said Rahma.
(With inputs from agencies)
